

The AI Scientist


Powered by multimodal patient data, for smarter biopharma decision making.

Identify immune-defined NSCLC subgroups and compare their survival on checkpoint inhibitors.



Built for every step of your pipeline

Ask questions in natural language to solve your challenges from early portfolio decisions to clinical trial decisions.



Prioritize targets

Rank therapeutic targets and gene candidates using statistical evidence from TCGA and MOSAIC datasets.

Second-Tier Targets (Good Tractability + Moderate Safety)

3. CLDN3 (Rank #3)


- **Antibody Tractability:** Good - transmembrane protein according to [Uniprot](#)
- **Expression Profile:** Moderate tumor selectivity with some liver expression (z-score: 1.0) according to [Human Protein Atlas \(HPA\)](#)
- **Safety Risk:** Moderate - medium liver expression requires monitoring
- **Development Status:** Established target with known therapeutic approaches

4. CLDN4 (Rank #4)

- **Antibody Tractability:** Good - transmembrane protein according to [Uniprot](#)
- **Expression Profile:** High kidney expression (z-score: 1.0) but tumor-associated according to [Human Protein Atlas \(HPA\)](#)
- **Safety Risk:** Moderate-High - kidney expression concerns
- **Development Status:** Active research target


Underexplored but Promising Targets

Clusters x Breast Cancer Gene Signature Expression




Characterize patient subgroups

Identify distinct populations based on multi-omics profiles and clinical outcomes.




Validate biomarkers across modalities

Test biomarkers and hypotheses across bulk RNA-seq, single-cell, spatial, and clinical data.



Generate comprehensive reports

Create publication-ready statistical reports for gene/target assessment, biomarker prioritization, and patent landscape analysis.



Connect biology to clinical outcomes

Integrate genomic, transcriptomic, and immune data to identify therapeutic opportunities and predict treatment response.

What makes K Pro different?



Powered by multimodal patient data

- MOSAIC spatial & multiomics dataset (2700 cancer samples, 11 tumor types)
- World-largest patient data network (104 hospitals)
- Ability to integrate your own data



A growing library of expert-grade AI skills

- Owkin-certified skills powered by 10 yrs of biomedical AI research
- KOL-inspired skills capturing the methodology of leading domain experts
- Code your own validated analytical workflows into custom reproducible skills



Interoperable orchestration of expert AI models

- Work with one agent that knows exactly which capabilities to activate
- Cutting-edge AI tools and models e.g. Pathology Explorer & OwkinZero
- Launch parallel campaigns to uncover breakthroughs from multiple approaches



Enterprise integration

- Integration with client workflows and applications
- Complement with your own data securely
- Encode your own workflows into custom executable AI skills

EXAMPLE USE CASES

Solving actual pharma R&D challenges in minutes

K Pro uses a single intelligent orchestrator that dynamically selects and combines specialized AI skills to solve your challenges across drug discovery and development.

Early portfolio decisions

Assess drug/program opportunities with confidence.

Population & indication decisions

Define the right patient populations and predictive biomarkers before your trial.

Clinical trial decisions

Enrich early clinical trial data with real-world insights.



Book a demo

Discover how K Pro can transform your drug discovery and development. Scan the QR code to book a demo with our team to explore how we can support your specific needs.



Get in touch with us at owkin.com/contact

© 2026 Owkin, Inc | Public information | Ref. 059V4

 **OWKIN.COM**